Long-term efficacy of dendritic cell vaccines combined with cytokine-induced killer cells in the treatment of metastatic renal cell carcinoma
10.3872/j.issn.1007-385x.2019.06.013
- VernacularTitle:DC疫苗联合细胞因子诱导的杀伤细胞治疗转移性肾癌的长期疗效分析
- Author:
YANG Yanli
1
;
WANG Danhong
1
;
LIAO Li
1
;
SUN Peng
1
;
HU Liangding
1
;
CHEN Hu
1
Author Information
1. (Department of Hematopoietic Stem Cell Transplantation, the Fifth Medical Center of Chinese PLAGeneral Hospital
- Publication Type:Journal Article
- Keywords:
metastatic renal cell carcinoma;
dendritic cell (DC);
tumor vaccines;
cytokine-induced killer (CIK) cell;
long-term clinical efficacy
- From:
Chinese Journal of Cancer Biotherapy
2019;26(6):695-699
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the long-term clinical efficacy and follow-up of dendritic cell (DC) vaccines in combination with cytokine-induced killer cell (CIK) treatment in metastatic renal cell carcinoma. Methods: From January 2011 to December 2013, 29 patients with metastatic renal cell carcinoma (pathologically confirmed as renal clear cell carcinoma) were treated by DC vaccines-CIK at the Department of Hematopoietic Stem Cell Transplantation, the Fifth Medical Center of Chinese PLA General Hospital. The 29 patients included 24 male and 5 female, with a median age of 57(32-81) years old. Mature DC vaccine was obtained by gene transfection technology and CIK cells were obtained by i n v i t r o culture; and DC vaccine-CIK was infused back to patients through lymphatic drainage area and vein by each course. Twelve patients received first line treatment, 6 patients received second line treatment after the disease progression by targeted drug therapy or cytokine therapy, and 11 patients received third-linetreatment or above. The long-term clinical efficacy and overall survival rate were evaluated. Results: The median follow-up time was 5 (1-7) years. Treatment cycle was over 2 (2-23) cycles. One case (3.4%) achieved complete remission, 9 cases (31%) achieved partial responses, 13 cases (44.8%) demonstrated stable disease over 3 months and 6 patients (20.7%) developed progressive disease. The objective response rate was 34.4%,and the disease control rate was 79.2%. Stable disease for more than one year realized in 19 cases (65.5%). The 1-, 3- and 5-year survival rates were 93.1% (27/29), 65.5% (20/29) and 51.7% (15 / 29), respectively. Neither the median progression-free survival (PFS) nor the median survival time was achieved. No adverse reactions above grade 3 were observed during treatment. Conclusion: DC vaccines-CIK therapy for the treatment of metastatic renal cell carcinoma is affirmative; it achieved good disease control and long-term survival with controllable safety, and prolonged the survival time for advanced renal cell carcinoma patients.
- Full text:20190613.pdf
